US 10392439
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
granted A61KA61K2039/505A61K2039/577
Quick answer
US patent 10392439 (Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61K2039/577, A61K39/395, A61K45/06